Orelabrutinib is an orally active and irreversible inhibitor of Bruton's tyrosine kinase (BTK).

1655504-04-3

C26H25N3O3

427.5

ICP-022;Orelabrutinib

[1]Wei Xu, et al. Safety, Tolerability and Efficacy of Orelabrutinib, Once a Day, to Treat Chinese Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Cell Leukemia. Blood (2019) 134 (Supplement_1): 4319.

DMSO:250 mg/mL (584.80 mM),Need ultrasonic
Powder: -20°C for 3 years
In solvent: -80°C for 2 years